GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carna Biosciences Inc (TSE:4572) » Definitions » Beta

Carna Biosciences (TSE:4572) Beta : 1.28 (As of Nov. 28, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Carna Biosciences Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-11-28), Carna Biosciences's Beta is 1.28.


Carna Biosciences Beta Historical Data

The historical data trend for Carna Biosciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carna Biosciences Beta Chart

Carna Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.15 1.79 1.92 1.35 1.60

Carna Biosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.31 1.60 1.27 1.31

Competitive Comparison of Carna Biosciences's Beta

For the Biotechnology subindustry, Carna Biosciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Beta distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Beta falls into.



Carna Biosciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Carna Biosciences  (TSE:4572) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Carna Biosciences Beta Related Terms

Thank you for viewing the detailed overview of Carna Biosciences's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Carna Biosciences Business Description

Traded in Other Exchanges
N/A
Address
BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.

Carna Biosciences Headlines

No Headlines